Niagen Bioscience has launched Niagen Skincare Innovation Lab and introduced Niagen NanoCloud, its first topical skincare product powered by patented nicotinamide riboside. The limited-release product addresses NAD+ degradation in water-based formulations through sealed, waterless sachets that maintain ingredient stability until use. The dermatologist-tested formula combines Niagen with hyaluronic acid, pullulan, squalane and vitamin E. A six-week consumer study of 37 participants showed visible improvements in skin texture, hydration and radiance within two weeks. The launch positions Niagen Bioscience in the global skincare market, valued at $122.11 billion in 2025 and projected to reach $227.13 billion by 2034. Niagen NanoCloud is available on truniagen.com for $59 per 30-sachet unit.

Niagen Bioscience has launched Niagen Skincare Innovation Lab, a product platform translating its NAD+ science into skincare, and debuted Niagen NanoCloud, a limited-release topical product powered by its patented nicotinamide riboside ingredient. The dermatologist-tested product addresses NAD+ degradation in water-based formulations through a sealed, waterless sachet format that preserves potency until use. When mixed with serum or moisturiser, it delivers a precision-dosed treatment containing hyaluronic acid, pullulan, squalane and vitamin E. A consumer study showed visible improvements in skin texture and hydration within two weeks. The launch targets the global skincare market, valued at $122 billion in 2025 and projected to reach $227 billion by 2034. Niagen NanoCloud is available at truniagen.com for $59, containing 30 sachets.

Niagen Bioscience reported 16% year-over-year revenue growth in Q4 2025, reaching $33.8 million, whilst full-year 2025 net revenue grew 30% to $129.4 million. The Nasdaq-listed company ended the year with $64.8 million in cash and no debt. The firm secured a patent for nicotinamide riboside and derivatives in intravenous and injectable formulations, initially launching one SKU targeting the biohacker and longevity communities. CEO Rob Fried said the injections would be priced lower than IV treatments. However, Niagen faces challenges including increased competition in the NAD space and FDA uncertainty around NMN's dietary supplement status. Its No Park Parkinson's study failed to achieve its primary endpoint. The company projects more conservative 10-15% growth for 2026, down from 2025's 30%.